EUR 0.07
(0.0%)
Year | Total Assets | Total Assets Growth |
---|---|---|
2023 | 3.74 Million EUR | -84.16% |
2022 | 23.65 Million EUR | 11.37% |
2021 | 21.24 Million EUR | -35.24% |
2020 | 32.8 Million EUR | 121.95% |
2019 | 14.77 Million EUR | -20.03% |
2018 | 18.48 Million EUR | 32.79% |
2017 | 13.91 Million EUR | -4.08% |
2016 | 14.5 Million EUR | 37.65% |
2015 | 10.54 Million EUR | 121.78% |
2014 | 4.75 Million EUR | 180.76% |
2013 | 1.69 Million EUR | 60.21% |
2012 | 1.05 Million EUR | 0.0% |
Year | Total Assets | Total Assets Growth |
---|---|---|
2024 Q2 | 891.68 Thousand EUR | 0.0% |
2023 FY | 3.74 Million EUR | -84.16% |
2023 Q4 | 3.74 Million EUR | 0.0% |
2023 Q2 | 5.75 Million EUR | 0.0% |
2022 Q2 | 27.05 Million EUR | 0.0% |
2022 FY | 23.65 Million EUR | 11.37% |
2022 Q4 | 23.65 Million EUR | 0.0% |
2021 FY | 21.24 Million EUR | -35.24% |
2021 Q2 | 32.41 Million EUR | 0.0% |
2021 Q4 | 21.24 Million EUR | 0.0% |
2020 Q4 | 32.8 Million EUR | 0.0% |
2020 FY | 32.8 Million EUR | 121.95% |
2020 Q2 | 18.54 Million EUR | 0.0% |
2019 FY | 14.77 Million EUR | -20.03% |
2019 Q2 | 16.58 Million EUR | 0.0% |
2019 Q4 | 15.1 Million EUR | 0.0% |
2018 Q4 | 18.48 Million EUR | 0.0% |
2018 FY | 18.48 Million EUR | 32.79% |
2018 Q2 | 9.67 Million EUR | 0.0% |
2017 Q2 | 10.69 Million EUR | 0.0% |
2017 FY | 13.91 Million EUR | -4.08% |
2017 Q4 | 13.91 Million EUR | 0.0% |
2016 Q2 | 15.84 Million EUR | 0.0% |
2016 FY | 14.5 Million EUR | 37.65% |
2016 Q4 | 14.5 Million EUR | 0.0% |
2015 Q4 | 10.54 Million EUR | 0.0% |
2015 Q2 | 12.89 Million EUR | 0.0% |
2015 FY | 10.54 Million EUR | 121.78% |
2014 Q4 | 4.75 Million EUR | 0.0% |
2014 Q2 | 2.74 Million EUR | 0.0% |
2014 FY | 4.75 Million EUR | 180.76% |
2013 FY | 1.69 Million EUR | 60.21% |
2013 Q4 | 1.69 Million EUR | 0.0% |
2012 FY | 1.05 Million EUR | 0.0% |
Name | Total Assets | Total Assets Difference |
---|---|---|
ABIONYX Pharma SA | 14.71 Million EUR | 74.529% |
ABIVAX Société Anonyme | 327.06 Million EUR | 98.854% |
Adocia SA | 24.95 Million EUR | 84.986% |
Aelis Farma SA | 26.28 Million EUR | 85.743% |
Biophytis S.A. | 11.93 Million EUR | 68.609% |
Advicenne S.A. | 12.4 Million EUR | 69.801% |
genOway Société anonyme | 31.84 Million EUR | 88.233% |
IntegraGen SA | 8 Million EUR | 53.167% |
Medesis Pharma S.A. | 1.92 Million EUR | -94.503% |
Neovacs S.A. | 47.53 Million EUR | 92.118% |
NFL Biosciences SA | 3.97 Million EUR | 5.638% |
Plant Advanced Technologies SA | 14.91 Million EUR | 74.876% |
Sensorion SA | 46.49 Million EUR | 91.941% |
Theranexus Société Anonyme | 7.23 Million EUR | 48.233% |
TME Pharma N.V. | 2.49 Million EUR | -50.412% |
Valbiotis SA | 33.24 Million EUR | 88.731% |
TheraVet SA | 7.53 Million EUR | 50.27% |
Valerio Therapeutics Société anonyme | 35.27 Million EUR | 89.378% |
DBV Technologies S.A. | 165.65 Million USD | 97.738% |
Genfit S.A. | 173.87 Million EUR | 97.845% |
GeNeuro SA | 6.31 Million EUR | 40.649% |
Innate Pharma S.A. | 184.19 Million EUR | 97.966% |
Inventiva S.A. | 69.13 Million EUR | 94.581% |
MaaT Pharma SA | 42.93 Million EUR | 91.273% |
MedinCell S.A. | 36.94 Million EUR | 89.859% |
Nanobiotix S.A. | 93.89 Million EUR | 96.01% |
OSE Immunotherapeutics SA | 81.9 Million EUR | 95.425% |
Poxel S.A. | 4.82 Million EUR | 22.315% |
GenSight Biologics S.A. | 9.08 Million EUR | 58.768% |
Transgene SA | 45.21 Million EUR | 91.714% |
Valneva SE | 469.39 Million EUR | 99.202% |